Of the nine strategies determined to be potentially effective in preventing post–cardiac surgery AKI, five (natriuretic peptides, nitroprusside, levosimendan, NAC with carvedilol, and dexmedetomidine) and four (fenoldopam, RIPC, EPO, and tolvaptan) were supported by moderate-confidence and low-confidence evidence, respectively. This evidence concerns the gene EPO and acute kidney injury.